SG11201810602YA - Method of treating liver fibrosis - Google Patents

Method of treating liver fibrosis

Info

Publication number
SG11201810602YA
SG11201810602YA SG11201810602YA SG11201810602YA SG11201810602YA SG 11201810602Y A SG11201810602Y A SG 11201810602YA SG 11201810602Y A SG11201810602Y A SG 11201810602YA SG 11201810602Y A SG11201810602Y A SG 11201810602YA SG 11201810602Y A SG11201810602Y A SG 11201810602YA
Authority
SG
Singapore
Prior art keywords
international
liver fibrosis
pct
treating liver
english
Prior art date
Application number
SG11201810602YA
Inventor
Zhenhua Miao
Israel Charo
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11201810602YA publication Critical patent/SG11201810602YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIP0 I Iiiimmoimiolollmolommioloiollmoiomionom oimIE (10) International Publication Number WO 2017/210526 Al PCT (51) International Patent Classification: A61K 31/4375 (2006.01) A61K 31/18 (2006.01) (21) International Application Number: PCT/US2017/035628 (22) International Filing Date: 02 June 2017 (02.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,086 03 June 2016 (03.06.2016) US (71) Applicant: CHEMOCENTRYX, INC. [US/US]; 850 Maude Avenue, Mountain View, CA 94043 (US). (72) Inventors: MIAO, Zhenhua; 6891 Dartmoor Way, San Jsoe, CA 95129 (US). CHARO, Israel; 850 Maude Av- enue, Mountain View, CA 94043 (US). (74) Agent: MARSHALL, Ryan, L.; Brinks Gilson & Lione, P.O. Box 10087, Chicago, IL 60610 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) = (54) Title: METHOD OF TREATING LIVER FIBROSIS Figure 1: Change in body weight in HFD/fructose-induced NASH model Body Weight 80- Treatment Started 60- Z C D 40- rl 0 CO 20- 0 0 10 20 30 40 50 Cl> 14\") Weeks 1-1 © (57) : A method of treating liver fibrosis with CCR2 antagonists is provided. The liver fibrosis may be associated with non- e , ' alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type C..? 2 diabetes mellitus (T2DM) or metabolic syndrome (MS). — Compound 1 SC Vehicle — Control Diet
SG11201810602YA 2016-06-03 2017-06-02 Method of treating liver fibrosis SG11201810602YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345086P 2016-06-03 2016-06-03
PCT/US2017/035628 WO2017210526A1 (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Publications (1)

Publication Number Publication Date
SG11201810602YA true SG11201810602YA (en) 2018-12-28

Family

ID=60479090

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202012080UA SG10202012080UA (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis
SG11201810602YA SG11201810602YA (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202012080UA SG10202012080UA (en) 2016-06-03 2017-06-02 Method of treating liver fibrosis

Country Status (15)

Country Link
US (3) US10682344B2 (en)
EP (1) EP3463350B1 (en)
JP (2) JP2019517523A (en)
KR (1) KR102444366B1 (en)
CN (2) CN109475537A (en)
AU (1) AU2017274521B2 (en)
BR (1) BR112018074452A2 (en)
CA (1) CA3025671A1 (en)
ES (1) ES2966111T3 (en)
IL (1) IL263245B (en)
MX (1) MX2018014743A (en)
RU (1) RU2740902C2 (en)
SG (2) SG10202012080UA (en)
WO (1) WO2017210526A1 (en)
ZA (1) ZA201807992B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment for modulating gut microbiota
RU2740902C2 (en) * 2016-06-03 2021-01-21 Хемоцентрикс, Инк. Method of treating hepatic fibroses
KR102269305B1 (en) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 FXR (NR1H4) modulating compound
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CA3152584C (en) * 2016-11-10 2024-02-13 Galmed Research And Development Ltd. Treatment for fibrosis
CN110461328A (en) 2017-03-28 2019-11-15 吉利德科学公司 The therapeutic combination for treating liver disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
JP7263659B2 (en) 2018-02-02 2023-04-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド Nitrogen-containing benzoheterocyclic compound containing carboxylic acid group, method for preparation and use thereof
MX2020011562A (en) * 2018-06-12 2021-02-02 Sichuan Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof.
CN112996490A (en) * 2018-08-14 2021-06-18 阿沃林特有限公司 Method for treating primary sclerosing cholangitis
EP3890747A4 (en) * 2018-12-05 2022-08-03 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN113302190A (en) 2019-01-15 2021-08-24 吉利德科学公司 FXR (NR1H4) modulating compounds
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
WO2020181163A1 (en) * 2019-03-06 2020-09-10 Tobira Therapeutics, Inc. Lipid-based formulation of cenicriviroc
JP2022532706A (en) 2019-05-08 2022-07-19 アリゴス セラピューティクス，インコーポレーテッド THR-β regulator and its usage
CA3148434A1 (en) * 2019-07-30 2021-02-04 Kobiolabs, Inc. Composition and method for preventing, alleviating, or treating liver injury
KR102401535B1 (en) * 2019-07-30 2022-05-24 주식회사 고바이오랩 Composition for Preventing, Improving, or Treating Liver Injury
WO2021102251A1 (en) * 2019-11-22 2021-05-27 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
CN116942684A (en) * 2020-02-20 2023-10-27 甘莱制药有限公司 Pharmaceutical composition for treating steatohepatitis and preparation method thereof
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
AU2021358793A1 (en) * 2020-10-08 2022-05-12 Curome Biosciences Co., Ltd. Pharmaceutical composition for preventing or treating cholestatic liver disease, containing betaeta-lapachone as active ingredient

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013216D1 (en) * 2004-05-26 2009-04-23 Janssen Pharmaceutica Nv MERCAPTOIMIDAZOLE AS CCR2 RECEPTOR ANTAGONISTS
US7622583B2 (en) * 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
WO2006076644A2 (en) 2005-01-14 2006-07-20 Chemocentryx, Inc. Heteroaryl sulfonamides and ccr2
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007106797A2 (en) * 2006-03-14 2007-09-20 Janssen Pharmaceutica, Nv A method of use for substituted dipiperidine ccr2 antagonists
US8519135B2 (en) * 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
ES2358618T3 (en) * 2006-07-14 2011-05-12 Chemocentryx, Inc. TRIAZOL PIRIDIL BENCENOSULFONAMIDAS AS MODULATORS OF CCR2 OR CCR9 FOR THE TREATMENT OF ARTERIOSCLEROSIS.
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
BRPI0813695B8 (en) * 2007-07-12 2021-05-25 Chemocentryx Inc fused heteroaryl pyridyl and phenyl benzenesulfonamide compounds, composition, method of modulating ccr2 function, uses of compounds, and crystalline form
PE20100156A1 (en) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int NAFLD TREATMENT
SG10201701323TA (en) * 2008-08-18 2017-04-27 Amgen Fremont Inc Antibodies to ccr2
MX346393B (en) * 2009-12-17 2017-03-17 Centrexion Therapeutics Corp New ccr2 receptor antagonists and uses thereof.
CN103391931A (en) * 2011-02-25 2013-11-13 辉瑞有限公司 A method of treating liver fibrosis
CN103945695B (en) * 2011-09-16 2018-04-17 卡莱克汀医疗有限公司 For treating the galactolipin rhamnose galacturonic ester composition of nonalcoholic fatty liver disease and non-alcoholic fatty liver disease
AU2013258109A1 (en) * 2012-05-09 2014-10-30 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
TWI696462B (en) * 2013-07-10 2020-06-21 日商興和股份有限公司 The therapeutic agent for nonalcoholic fatty liver disease
RU2723559C2 (en) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Combined therapy with application of cenicriviroc for fibrosis treatment
RU2740902C2 (en) * 2016-06-03 2021-01-21 Хемоцентрикс, Инк. Method of treating hepatic fibroses

Also Published As

Publication number Publication date
US11357760B2 (en) 2022-06-14
BR112018074452A2 (en) 2019-03-19
IL263245B (en) 2021-09-30
JP2019517523A (en) 2019-06-24
EP3463350A1 (en) 2019-04-10
EP3463350A4 (en) 2020-01-29
IL263245A (en) 2018-12-31
RU2018145459A3 (en) 2020-07-09
JP7431931B2 (en) 2024-02-15
US20200268727A1 (en) 2020-08-27
CN109475537A (en) 2019-03-15
RU2018145459A (en) 2020-07-09
US20170348293A1 (en) 2017-12-07
KR102444366B1 (en) 2022-09-19
KR20190026687A (en) 2019-03-13
EP3463350B1 (en) 2023-09-13
JP2023022227A (en) 2023-02-14
ZA201807992B (en) 2023-10-25
US10682344B2 (en) 2020-06-16
CA3025671A1 (en) 2017-12-07
ES2966111T3 (en) 2024-04-18
RU2740902C2 (en) 2021-01-21
WO2017210526A1 (en) 2017-12-07
SG10202012080UA (en) 2021-01-28
AU2017274521B2 (en) 2021-08-19
CN115154467A (en) 2022-10-11
MX2018014743A (en) 2019-04-11
US20220313668A1 (en) 2022-10-06
AU2017274521A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
SG11201810602YA (en) Method of treating liver fibrosis
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201900135YA (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
SG11201808125RA (en) Methods for solid tumor treatment
SG11201803906PA (en) Control of cellular redox levels
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201807474SA (en) Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201810430WA (en) Heater assembly for an aerosol-generating system
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201900471VA (en) Combination therapy for copd
SG11201901995TA (en) Crystalline and salt forms of ppar agonist compounds
SG11201804123VA (en) Modulators of kv3 channels to treat pain
SG11201805204WA (en) Nicotine particle capsule
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate
SG11201811311VA (en) Compounds for imaging tau protein aggregates
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound